


Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses
EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H